Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials.


Using an I.M.S. LifeLink dataset (19 September 2014-11 September 2015), we compared U.S. cardiologist prescribing of the reduced dose of apixaban (2.5 mg) or rivaroxaban (15 mg) to utilization in their corresponding nonvalvular atrial fibrillation registration randomized trials. Of all prescriptions written by cardiologists for these agents, 20.8% of… (More)
DOI: 10.1185/03007995.2016.1170672


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics